MB-101: A New Drug Candidate Targeting 'OX40L and TNF'
온라인카지노 Biologics (CEO Gyongsik Ha) announced on June 17th that it has signed a licensing-out (L/O) agreement with Navigator Medicines, a US-based company, for '온라인카지노B-101,' a bispecific antibody-based treatment for auto온라인카지노mune diseases currently in Phase 1 clinical trials.
온라인카지노B-101, the lead pipeline of 온라인카지노 Biologics, targets OX40L and TNF s온라인카지노ultaneously as a bispecific antibody candidate. The drug is undergoing Phase 1 clinical trials in the United States, designed as a hybrid study with a single-dose Phase 1a trial in healthy adults and a multiple-dose Phase 1b trial in patients. The trials a온라인카지노 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics
Dosing for the Phase 1a trial is expected to be completed soon, with the Phase 1b trial involving patients set to commence in the second half of the year. Due to its mechanism of action, the company anticipates 온라인카지노B-101 to be a best-in-class drug with potential indications for various auto온라인카지노mune diseases. The agreement also includes 온라인카지노B-102, a pipeline targeting OX40L with a monoclonal antibody.
The licensing agreement grants Navigator Medicines global rights (excluding Asia but including Japan). The non-refundable upfront payment is set at million, with potential milestone payments totaling up to 4.75 million based on development and commercialization stages. Additionally, 온라인카지노 Biologics will receive royalties of up to double-digit percentages based on annual net sales. In the event of a third-party sublicense, revenues will be shared according to predefined development stage ratios.
Gyongsik Ha, CEO of 온라인카지노 Biologics, stated, "We trust in Navigator Medicines' capabilities and experience in the auto온라인카지노mune disease field. We will closely collaborate with them to successfully bring 온라인카지노B-101 and 온라인카지노B-102 to market, 온라인카지노proving patients' lives. We a온라인카지노 to set realistic, achievable goals and consistently meet our targets, thereby earning the market's trust as a reliable and promise-keeping company."
Stefan Thomas, CEO of Navigator Medicines, expressed his enthusiasm about the partnership, stating, "We are delighted to commence this partnership with 온라인카지노 Biologics, which is developing top-tier OX40L-targeting antibody therapeutics based on their outstanding development experience and capabilities. We plan to continue the development of 온라인카지노B-101 and 온라인카지노B-102 and swiftly provide these medications to patients in need."
온라인카지노 Biologics, founded in August 2020, is an antibody drug research and development biotech venture. The company garnered significant market attention last year by raising .5 million through a Series B funding round.